Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

被引：71

作者：

Abdel-Rahman, Omar ^{[1
]}

ElHalawani, Hesham ^{[1
]}

Fouad, Mona ^{[2
]}

机构：

[1] Ain Shams Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt

[2] Ain Shams Univ, Fac Med, Dept Med Microbiol & Immunol, Cairo, Egypt

来源：

IMMUNOTHERAPY | 2015年 / 7卷 / 11期

关键词：

colitis; diarrhea; ipilimumab; nivolumab; DOUBLE-BLIND; METASTATIC MELANOMA; ANTI-CTLA4; ANTIBODY; ADVERSE EVENTS; OPEN-LABEL; IPILIMUMAB; NIVOLUMAB; SAFETY; TOXICITIES; BLOCKADE;

D O I：

10.2217/imt.15.87

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: We performed a meta-analysis of the risk of selected gastrointestinal toxicities associated with immune checkpoint inhibitors. Patients & methods: Eligible studies included randomized trials of patients with solid tumors on ipilimumab, nivolumab, pembrolizumab, tremelimumab, pidilizumab and atezolizumab, describing events of diarrhea, vomiting or colitis. Results: After exclusion of ineligible studies, a total of ten clinical trials were considered eligible for the meta-analysis. The relative risk of all-grade diarrhea, vomiting and colitis was 1.64 (95% CI: 1.19-2.26; p = 0.002), 0.72 (95% CI: 0.49-1.07; p = 0.1), 10.35 (95% CI: 5.78-18.53; p < 0.00001), respectively. Conclusion: Our meta-analysis has demonstrated that immune checkpoint inhibitors are associated with a significantly increased risk of all grade and high-grade colitis.

引用

页码：1213 / 1227

页数：15

共 51 条

[1] Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis [J].